Krka wins valsartan patent dispute with Novartis
This article was originally published in Scrip
Executive Summary
Novartis has dropped its litigation over the alleged infringement of two of its patents relating to the angiotensin receptor blocker valsartan (Novartis's Diovan) in Slovenia by the local company Krka.